Scholars@Duke
construction release_alert
The Scholars Team is working with OIT to resolve some issues with the Scholars search index
cancel

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

Publication ,  Journal Article
Ettinger, DS; Wood, DE; Akerley, W; Bazhenova, LA; Borghaei, H; Camidge, DR; Cheney, RT; Chirieac, LR; D'Amico, TA; Dilling, T; Dobelbower, M ...
Published in: J Natl Compr Canc Netw
July 2016
Published version (DOI) Link to item

These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

Duke Scholars

Thomas Anthony D'Amico
Author Thomas Anthony D'Amico Surgery, Cardiovascular and Thoracic Surgery
Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2016.0087

EISSN

1540-1413

Publication Date

July 2016

Volume

14

Issue

7

Start / End Page

825 / 836

Location

United States

Related Subject Headings

  • Pleural Neoplasms
  • Oncology & Carcinogenesis
  • Mesothelioma, Malignant
  • Mesothelioma
  • Lung Neoplasms
  • Humans
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., … Hughes, M. (2016). NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw, 14(7), 825–836. https://doi.org/10.6004/jnccn.2016.0087
Ettinger, David S., Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, et al. “NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.” J Natl Compr Canc Netw 14, no. 7 (July 2016): 825–36. https://doi.org/10.6004/jnccn.2016.0087.
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw. 2016 Jul;14(7):825–36.
Ettinger, David S., et al. “NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.” J Natl Compr Canc Netw, vol. 14, no. 7, July 2016, pp. 825–36. Pubmed, doi:10.6004/jnccn.2016.0087.
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D’Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw. 2016 Jul;14(7):825–836.

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2016.0087

EISSN

1540-1413

Publication Date

July 2016

Volume

14

Issue

7

Start / End Page

825 / 836

Location

United States

Related Subject Headings

  • Pleural Neoplasms
  • Oncology & Carcinogenesis
  • Mesothelioma, Malignant
  • Mesothelioma
  • Lung Neoplasms
  • Humans
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis